Michael T. Redman, CEO & Board Member

Mr. Redman is the chief executive officer of Oncolix, Inc. and has served in this position since formation of the company in November of 2006.

Prior to Oncolix, Mr. Redman was the CEO of Bone Medical, a public company focused in the area of oral peptide delivery of products related to musculoskeletal disorders. Immediately prior to Bone Medical, Mr. Redman was the CEO and co-founder of Opexa Pharmaceuticals, which commenced operations in February of 2001 and was successfully sold to PharmaFrontiers Corporation in November of 2004. PharmaFrontiers later reorganized the company, which is now named Opexa Therapeutics, a NASDAQ-listed company.

His career spans over 25 years in the pharmaceuticals and biotechnology industry and encompasses leadership in sales, marketing, business and commercial development. In addition to the three companies in which he served as CEO, Mr. Redman also held key management positions with Zonagen, Aronex Pharmaceuticals, Biovail, and American Home Products.

Mr. Redman has been instrumental in closing multiple pharmaceutical licensing deals, both domestic and international. These deals include in-licensing of university and NIH intellectual property, acquisitions and divestitures. He is an active member of the Licensing Executives Society and formerly served on its Executive Committee. Mr. Redman earned a BA in Biology from the University of Missouri and a Masters in Business Administration from the University of Phoenix.

Donald Payne, CPA, MBA, SVP of Finance and Administration

Mr. Payne serves as the Senior Vice President of Finance and Administration.  He is responsible for financial, accounting, intellectual property administration and general administration of the Company’s activities.

Mr. Payne has held various senior management positions at Nanospectra Biosciences, Sensus Drug Development, LifeCell Corporation, Aprogenex and Entex Energy.  His financial experience includes initial public offerings on the New York and American Stock Exchanges and numerous private offerings.  He has is a co-author of 9 scientific publications and is a co-inventor of 4 issued or pending patent applications.  At Nanospectra, he led the preclinical development and toxicity program, successfully filed an IDE for a cancer therapy, and led the company through its initial pilot human trial.

Mr. Payne received an MBA from Rice University in 1992, a BBA from Texas A&M University in 1976 and is a licensed CPA (Texas, 1978).  He is currently a Director and the Chairman of the Audit Committee of Pressure Biosciences (Nasdaq:PBIO) and a Director of Nanospectra Biosciences.  He also holds various advisory positions to academic and economic development entities.  

George Peoples, Jr., MD, FACS.

Dr. Peoples graduated from West Point in 1984 and from Johns Hopkins School of Medicine in 1988. After a surgical internship at Walter Reed Army Medical Center (WRAMC), he completed his surgical training at the Brigham and Women's Hospital in Boston, MA in 1996. During that time, Dr. Peoples also completed a research fellowship at the Laboratory of Biologic Cancer Therapy at Harvard Medical School.

Dr. Peoples completed a surgical oncology fellowship at MD Anderson Cancer Center in Houston, TX in 1998. He was the previous Chief, Surgical Oncology at WRAMC from 1998-2006 and now serves in that role at Brooke Army Medical Center in San Antonio. He is the Director and Principal Investigator of the Cancer Vaccine Development Program associated with the Uniformed Services University of the Health Sciences and the Deputy Director of the United States Military Cancer Institute.

Dr. Peoples holds 7 patents and 5 INDs and is currently the PI on 7 cancer vaccine clinical trials being conducted at 12 military and civilian sites. He has written extensively on the immune response to cancer.

William E. Gannon, Jr., M.D., M.B.A. Chief Regulatory Officer

William E. Gannon, MD, MBA, is the Chief Regulatory Officer of Oncolix. In addition to receiving his medical training and clinical work at Ross University, Case Western Reserve and George Washington University, Dr. Gannon obtained an M.B.A. in 1988 and has since built a wealth of experience in the management of clinical trials including designing the trials and building operational teams to ensure their successful completion.

Dr. Gannon has over 20 years experience in the regulatory and clinical trials arena.  He has held positions in multinational CROs, medical device, biotech and pharmaceutical firms, primarily in the field of cancer. Dr. Gannon has substantial expertise with protocol development and clinical trial management. He has been responsible for numerous regulatory submissions and execution of Phase I through Phase IV trials in the US, Europe and Asia.